Compare Amphastar Pharmaceuticals Inc (AMPH) vs Futu Holdings Ltd (FUTU) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Futu Holdings trades at $96.33, down 0.71% on the day, with a neutral technical signal and key support at $95. The company reported strong 2025 revenue of $22.85 billion and net income of $11.34 billion, with high profitability margins. However, recent earnings misses and a securities class action lawsuit have introduced uncertainty.

The outlook is mixed: solid fundamentals and a 'Buy' analyst consensus support upside, but legal risks and earnings volatility pose significant headwinds. Investors should weigh the attractive valuation against potential regulatory and litigation overhangs.